NASDAQ:ALBOAlbireo Pharma Stock Price, Forecast & News

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALBO shares have increased by 46.2% and is now trading at $25.77. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Albireo Pharma.

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Albireo Pharma.

Albireo Pharma Inc (NASDAQ:ALBO) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($2.23) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.39) by $0.84. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.19 million. Albireo Pharma had a negative return on equity of 72.82% and a negative net margin of 730.55%. View Albireo Pharma's earnings history.

5 brokerages have issued 12 month price targets for Albireo Pharma's shares. Their forecasts range from $39.00 to $62.00. On average, they expect Albireo Pharma's share price to reach $52.75 in the next year. This suggests a possible upside of 104.7% from the stock's current price. View analysts' price targets for Albireo Pharma.

Media coverage about ALBO stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Albireo Pharma earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAlbireo Pharma.

Some companies that are related to Albireo Pharma include Akebia Therapeutics (AKBA), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Akcea Therapeutics (AKCA), I-Mab (IMAB), CytoDyn (CYDY), ZEALAND PHARMA/S (ZEAL), Arcus Biosciences (RCUS), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA), Intra-Cellular Therapies (ITCI), Arvinas (ARVN) and Karyopharm Therapeutics (KPTI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), Exelixis (EXEL), Palatin Technologies (PTN), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Viking Therapeutics (VKTX), Arcturus Therapeutics (ARCT), Alibaba Group (BABA) and Cornerstone Total Return Fund (CRF).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (13.09%), Federated Hermes Inc. (12.77%), ArrowMark Colorado Holdings LLC (6.49%), BlackRock Inc. (5.13%), Chicago Capital LLC (3.30%) and Prosight Management LP (2.21%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View institutional ownership trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Investments LP, Wells Fargo & Company MN, Victory Capital Management Inc., Victory Capital Management Inc., Parametric Portfolio Associates LLC, and MAI Capital Management. Company insiders that have sold Albireo Pharma company stock in the last year include Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford. View insider buying and selling activity for Albireo Pharma.

ALBO stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Chicago Capital LLC, Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, Prosight Management LP, BlackRock Inc., Deutsche Bank AG, and Geode Capital Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc, and Ronald Harold Wilfred Cooper. View insider buying and selling activity for Albireo Pharma.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $25.77.

Albireo Pharma has a market capitalization of $386.03 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.

The official website for Albireo Pharma is www.albireopharma.com.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]